The biotech is tackling common cardiovascular conditions by targeting risk factors like high cholesterol, triglycerides, and ...
The deal involves non-dilutive cash in exchange for royalties, if the gene therapies are approved, and an equity investment from Oberland Capital.
The partnership will leverage Sanyou's AI-based libraries of over one trillion antibody gene sequences and Baiyunshan Xihe's supply chain expertise.
The firm announced it has aligned with the US Food and Drug Administration on the design of the Phase III study, which could support a biologics license application.
Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...
The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results